Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Opthea Ltd ADR (OPT)

Opthea Ltd ADR (OPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 195,045
  • Shares Outstanding, K 58,395
  • Annual Sales, $ 120 K
  • Annual Income, $ -220,240 K
  • EBIT $ 0 M
  • EBITDA $ -192 M
  • 60-Month Beta 1.07
  • Price/Sales 1,560.36
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.14 +14.92%
on 11/25/24
3.86 -6.52%
on 12/03/24
+0.45 (+14.20%)
since 11/22/24
3-Month
3.09 +16.78%
on 11/22/24
5.45 -33.79%
on 10/14/24
-0.29 (-7.47%)
since 09/23/24
52-Week
1.79 +101.59%
on 06/27/24
5.45 -33.79%
on 10/14/24
+1.18 (+48.80%)
since 12/22/23

Most Recent Stories

More News
Opthea Limited to Present Phase 3 Trial Data at 43rd Annual J.P. Morgan Healthcare Conference

Opthea will present Phase 3 trial updates at the J.P. Morgan Healthcare Conference on January 15, 2025.Quiver AI SummaryOpthea Limited, a clinical-stage biopharmaceutical company focused on developing...

OPT : 3.61 (+8.04%)
Opthea Limited CEO to Present at Citi 2024 Global Healthcare Conference in Miami

Opthea Limited's CEO will speak at the Citi 2024 Global Healthcare Conference, discussing retinal disease therapies.Quiver AI SummaryOpthea Limited, a clinical-stage biopharmaceutical company focused on...

OPT : 3.61 (+8.04%)
Opthea Limited Appoints Kathy Connell as Non-Executive Director Ahead of Phase 3 Wet AMD Data Readout

Opthea appoints Kathy Connell as Non-Executive Director, enhancing business development expertise ahead of 2025 wet AMD data release.Quiver AI SummaryOpthea Limited has announced the appointment of Kathy...

OPT : 3.61 (+8.04%)
2 Stocks Under $10 Wall Street Says Are 'Strong Buys'

You can spend less and earn significant returns with these two cheap stocks.

TARA : 5.15 (-4.45%)
$SPX : 5,974.07 (+0.73%)
OPT : 3.61 (+8.04%)
Opthea To Present at Upcoming Investor Conferences

MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to...

OPT.AX : 0.755 (+4.14%)
OPT : 3.61 (+8.04%)
Opthea Presentation at The Retina World Congress 2022

MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel...

OPT.AX : 0.755 (+4.14%)
OPT : 3.61 (+8.04%)
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022

MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing...

OPT.AX : 0.755 (+4.14%)
OPT : 3.61 (+8.04%)
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting

MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing...

OPT.AX : 0.755 (+4.14%)
OPT : 3.61 (+8.04%)
Opthea strengthens its Board of Directors

Elects Mr. Quinton Oswald and Dr. ...

OPT.AX : 0.755 (+4.14%)
OPT : 3.61 (+8.04%)
Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies...

OPT.AX : 0.755 (+4.14%)
OPT : 3.61 (+8.04%)

Business Summary

Opthea Limited is a biotechnology company. It develops and commercializes therapies primarily for eye disease principally in Australia. Opthea Limited is based in South Yarra, Australia.

See More

Key Turning Points

3rd Resistance Point 3.95
2nd Resistance Point 3.78
1st Resistance Point 3.69
Last Price 3.61
1st Support Level 3.44
2nd Support Level 3.26
3rd Support Level 3.18

See More

52-Week High 5.45
Fibonacci 61.8% 4.05
Fibonacci 50% 3.62
Last Price 3.61
Fibonacci 38.2% 3.19
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar